Sanofi's multiple sclerosis drug Lemtrada showed strong results in the first year of an extended phase 3 study, reducing relapse rates in treated patients and improved disability outcomes, the company said this week.
The study results [file opens in PDF], released by Sanofi and subsidiary Genzyme, came as the European Medicines Agency and the FDA review Lemtrada for regulatory decisions expected later in 2013.
Sixty-seven percent of patients new to treatment and 55% of patients who had relapsed on prior therapy remained relapse-free a year into the extended study. More than 70% of each patient group showed improved or stable disability, while more than 80% of patients didn't require a third round of treatment during the trial.
Lemtrada's safety profile remained steady as no new risks emerged for patients on the drug; infections were the most common adverse events over the course of the extended study's first year.
The article Sanofi's Lemtrada Shines in Extended Study originally appeared on Fool.com.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.